Asian Penny Stocks To Watch In August 2026

As we move through August 2026, the Asian markets are capturing global attention with their resilience amidst geopolitical developments and economic shifts. In this context, penny stocks—often smaller or newer companies—remain a compelling area of interest for investors seeking growth opportunities at lower price points. Despite being an older term, they continue to hold relevance when backed by strong financials and solid fundamentals, offering potential upside without many of the typical risks associated with this segment.

Here's a peek at a few of the choices from the screener.

Maoyan Entertainment (SEHK:1896)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Maoyan Entertainment, an investment holding company, operates a platform in the entertainment industry in the People’s Republic of China with a market cap of approximately HK$5.69 billion.

Operations: The company's revenue is primarily derived from its business services segment, which generated CN¥4.63 billion.

Market Cap: HK$5.69B

Maoyan Entertainment, with a market cap of HK$5.69 billion, has shown impressive earnings growth, exceeding both its historical average and industry benchmarks. The company is trading below its estimated fair value by 16.2%, suggesting potential undervaluation. Despite robust past performance and strong liquidity with more cash than debt, recent guidance indicates a challenging period ahead due to a significant decline in China's film market box office revenue and moviegoer numbers. The company anticipates a loss for the first half of 2026, driven by underperforming films and increased investment in live performances amidst industry pressures.

• Navigate through the intricacies of Maoyan Entertainment with our comprehensive balance sheet health report here.
• Examine Maoyan Entertainment's earnings growth report to understand how analysts expect it to perform.

China Overseas Grand Oceans Group (SEHK:81)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: China Overseas Grand Oceans Group Limited is an investment holding company involved in property development and commercial property operations in the People’s Republic of China and Hong Kong, with a market cap of approximately HK$9.06 billion.

Operations: The company's revenue is primarily derived from property development, which generated CN¥36.38 billion, supplemented by CN¥493.37 million from commercial property operations.

Market Cap: HK$9.06B

China Overseas Grand Oceans Group, with a market cap of HK$9.06 billion, is experiencing mixed performance in the property development sector. Recent sales data shows a decline in monthly contracted sales and GFA for June 2026, though year-to-date figures indicate growth compared to last year. Despite stable weekly volatility and satisfactory net debt to equity ratio (32.8%), the company faces challenges with declining profit margins (0.8%) and negative earnings growth over the past year (-68.1%). The management team is experienced, but financial results were impacted by a large one-off loss of CN¥469.7 million in 2025.

• Unlock comprehensive insights into our analysis of China Overseas Grand Oceans Group stock in this financial health report.
• Review our growth performance report to gain insights into China Overseas Grand Oceans Group's future.

Chongqing Lummy Pharmaceutical (SZSE:300006)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Chongqing Lummy Pharmaceutical Co., Ltd. focuses on the research, development, manufacture, and sale of pharmaceutical products in China and has a market cap of CN¥5.65 billion.

Operations: The company generates revenue of CN¥759.50 million from its operations in China.

Market Cap: CN¥5.65B

Chongqing Lummy Pharmaceutical, with a market cap of CN¥5.65 billion, is navigating the pharmaceutical sector despite being unprofitable. The company has reduced its losses at a rate of 27.2% annually over the past five years and maintains a robust cash runway for over three years even if free cash flow declines significantly. Its short-term assets comfortably cover both short- and long-term liabilities, while debt levels have decreased from 32.6% to 22.5% in five years, supported by more cash than total debt. Recent board changes include new non-independent and independent directors elected in June 2026.

• Take a closer look at Chongqing Lummy Pharmaceutical's potential here in our financial health report.
• Explore historical data to track Chongqing Lummy Pharmaceutical's performance over time in our past results report.

Where To Now?

• Unlock more gems! Our Asian Penny Stocks screener has unearthed 1,056 more companies for you to explore.Click here to unveil our expertly curated list of 1,059 Asian Penny Stocks.
• Ready For A Different Approach? Trump's oil boom is here — pipelines are primed to profit. Discover the 23 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com